Ali Edraki, Ph.D.

Dr. Ali Edraki is the Director of Strategic Relationships at MPM BioImpact.

Prior to joining MPM BioImpact, Ali was on the Business Development team at Tessera Therapeutics, where he executed several partnerships to advance Tessera’s mission in bringing genetic medicines to patients and contributed to building Tessera’s innovative Gene Insertion technologies.

Ali performed his Ph.D. research on CRISPR-Cas genome engineering with Dr. Erik Sontheimer at the RNA Therapeutics Institute. He and his co-authors were among the first groups to harness CRISPR-Cas9 diversity to enable precision genome engineering tools. Ali was also a pioneer in the discovery and characterization of anti-CRISPR proteins; naturally-occurring enzymes that inhibit the activity of CRISPR-Cas9. Ali is the inventor on four patents and more than a dozen peer reviewed scientific publications.

Ali holds a Ph.D. in Biomedical Sciences from UMass Medical School and performed his postdoctoral fellowship at the Massachusetts Institute of Technology and Harvard Medical School. Ali received his B.S. in Biological Sciences from Cornell University.